New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 9, 2014
08:41 EDTESRX, GILDAttack on Gilead Sovaldi by Express Scripts 'noise,' says Maxim
After Bloomberg reported that Express Scripts (ESRX) said that it would attempt to build a coalition against the use of Gilead's (GILD) Sovaldi once a rival drug is approved, Maxim views Express Scripts' statement as "noise." The firm says that Sovaldi is not the most expensive HCV drug, and reiterates its view that Sovaldi provides "compelling" value, when including the cost of failure rates in a cost/benefit analysis. Maxim keeps a Buy rating on Gilead.
News For GILD;ESRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 3, 2015
07:08 EDTGILDAmerican Society for Clinical Pharmacology and Therapeutics holds meeting
Subscribe for More Information
March 2, 2015
09:34 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL MNTA CELG TSLA MCD ARUN GILD KO TWTR NFLX
February 27, 2015
07:37 EDTGILDGilead removed from the short-term buy list at Deutsche Bank
Subscribe for More Information
February 26, 2015
19:09 EDTGILDGilead announces Phase 3 results for once-daily single tablet HIV regimen
Gilead Sciences announced detailed 48-week results from two Phase 3 studies, Studies 104 and 111, evaluating its investigational once-daily single tablet regimen containing tenofovir alafenamide, or TAF, for the treatment of HIV-1 infection in treatment-naÔve adults. A regimen of elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and TAF 10 mg was found to be statistically non-inferior to Gileadís Stribild, containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, based on percentages of patients with HIV-1 RNA levels less than 50 copies/mL. A second analysis found that patients receiving the TAF regimen also had significantly better renal and bone laboratory parameters than those treated with Stribild. The data were presented in two late-breaker presentations at the 22nd Conference on Retroviruses and Opportunistic Infections in Seattle.
15:25 EDTGILDGilead announces 96% SVR12 rate in Phase 3 study of Harvoni
Subscribe for More Information
07:36 EDTESRXExpress Scripts price target raised to $90 from $85 at Leerink
Subscribe for More Information
February 25, 2015
15:30 EDTGILDGilead announces preclincal data on investigational TLR7 agonist
Subscribe for More Information
10:11 EDTESRXExpress Scripts says willing to do 'tranformational' deal
Subscribe for More Information
February 24, 2015
13:23 EDTESRXLeerink healthcare technology analyst holds analyst/industry conference call
Healthcare Tech & Distribution Analyst Larsen discusses th 2016 Pharmacy Benefits Management (PBM) selling season, the impact of the Hep C PBM formulary negotiations on the selling season and specialty drug trend and areas of opportunity for PBMs on an Analyst/Industry conference call to be held on March 5 at 2 pm.
09:35 EDTGILDActive equity options trading on open
Subscribe for More Information
February 23, 2015
18:02 EDTESRXOn The Fly: After Hours Movers
Subscribe for More Information
16:04 EDTESRXExpress Scripts sees Q1 EPS $1.07-$1.11, consensus $1.16
Subscribe for More Information
16:03 EDTESRXExpress Scripts sees FY15 EPS $5.35-$5.49, consensus $5.44
Subscribe for More Information
16:02 EDTESRXExpress Scripts reports Q4 EPS 1.39, consensus $1.38
Subscribe for More Information
16:00 EDTGILDOptions Update; February 23, 2015
Subscribe for More Information
15:23 EDTESRXNotable companies reporting after market close
Subscribe for More Information
09:39 EDTGILDActive equity options trading on open
Subscribe for More Information
07:16 EDTGILDMylan signs exclusive agreement with Gilead to distribute Solvaldi, Harvoni
Subscribe for More Information
06:28 EDTESRXExpress Scripts weekly volatility elevated into Q4 and outlook
Subscribe for More Information
February 19, 2015
09:35 EDTGILDOption volume leaders
Option volume leaders: AAPL TSLA TWTR MCD WMT PBR SPWR WFM GILD FB SCTY according to Track Data.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use